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Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell disorder with diverse clinical symptoms, a heterogeneous genetic background and variable response to treatment. Several acquired genetic abnormalities influence the outcome of the disease; prognostic risk stratification according to genetic alterations present at diagnosis in leukemic cells has, therefore, received increasing attention in AML in recent years. 1 Current prognostic factors are not sufficient to predict prognosis accurately, especially in AML with a normal karyotype (NK-AML). Inherited functional genomic polymorphisms are among the candidates explaining the heterogeneity of the prognoses.
Somatic gain-of-function mutation of the Janus kinase 2 (JAK2) gene located on chromosome 9p (c.1849G>T resulting in V617F) has been identified in BCR-ABL-negative myeloproliferative neoplasms. [2] [3] [4] Previous studies demonstrated that the presence of JAK2 V617F is associated with an inherited JAK2 haplotype designated as the 46/1 haplotype. [5] [6] [7] The 46/1 haplotype stretches through a 280-kb-long linkage disequilibrium block involving the JAK2, INSL4 and INSL6 genes. Carriers of the 46/1 haplotype have a higher risk of developing V617F-positive and -negative myeloproliferative neoplasms. [5] [6] [7] [8] [9] On rare occasions, the same mutation occurs in myelodysplastic syndromes and de novo AML. [10] [11] [12] [13] [14] In our recent study, 15 an inherited predisposition to JAK2 V617F-negative NK-AML was demonstrated in 46/1 haplotype carriers. To extend these observations, the current study was aimed at: (i) comparing disease characteristics (age, morphology and acquired cytogenetic or molecular genetic alterations at diagnosis of AML) between JAK2 46/1 haplotype carriers and non-carriers; and (ii) testing the prognostic impact of the 46/1 haplotype on AML outcome (remission and relapse rate, overall and disease-free survival, cause of death).
Design and Methods

Patients
The patients studied were 176 consecutively diagnosed individuals with AML [discovery cohort: 77 males/99 females; median age of disease onset: 48 years (range, 18- also studied. In this latter group, the minimum follow-up was 16 months (maximum, 32 months). Clinical data were collected retrospectively. Complete remission, early death (<28 days after the start of therapy), resistant disease, disease-free survival and overall survival were defined according to recommended criteria. 16 Infection as a cause of death was recorded in cases without any signs of leukemia (in remission or in aplasia) when ante-mortem clinical findings or autopsy results were conclusive for an infectious origin. During cytogenetic analysis, at least 20 metaphases were karyotyped and abnormalities were described according to the International System for Human Cytogenetic Nomenclature (ISCN 2005) . Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) and nucleophosmin 1 (NPM1) insertion mutations were tested by polymerase chain reaction followed by Genescan analysis. 17, 18 Participants signed informed consent, and the study was approved by the Regional Ethics Committee. Table 1 ). The distributions of FLT3 ITD and NPM1 mutation among 46/1 carriers and non-carriers were the same.
In order to confirm our observations, we included an independent validation cohort of AML patients (n=74) in the study. The pretreatment clinical characteristics of the validation cohort are presented in Online Supplementary 
Prognostic impact of the 46/1 haplotype
Disease outcome data according to 46/1 haplotype are presented in Table 2 for the discovery cohort. In the entire discovery cohort, 46/1 haplotype carriers and non-carriers had similar complete remission rates, while there was a tendency towards a lower complete remission rate among 46 Table S4 . We were not able to confirm our observations on overall survival, disease-free survival or rate of death caused by infection in the NK-AML subgroup within the validation cohort, probably because of the low number of cases, the shorter maximum follow-up period and the more pronounced heterogeneity of treatment protocols (less intensive).
Discussion
The inherited genetic background of an individual may not only increase disease susceptibility, but genomic polymorphisms may also play an important role in determining treatment outcome. Until recently, genetic variants involved in drug metabolism or DNA repair were considered the main possible modifiers of treatment outcome. [21] [22] [23] Single nucleotide polymorphisms of genes involved in hematopoietic signal-transduction were investigated less frequently. 24, 25 In this study, we report an association of the JAK2 46/1 haplotype with disease characteristics and treatment out- 26, 27 Retrieving haplotype information from the HapMap Project on rs12343867 and rs2230724 in a Chinese population revealed that the above polymorphisms are not in complete linkage (estimated haplotype frequencies of rs12343867/rs2230724: T/G: 57%, C/A: 23%, T/A: 18%, C/G: 2%, D': 0.892; P<0.000). 28 In Chinese AML patients, the AA genotype of rs2230724 was significantly associated with higher complete remission rate, and the GG genotype with early death. The different findings in our study may be explained by the incomplete linkage of the polymorphisms tested, by different ethnic backgrounds of the cohorts tested or by different therapeutic regimens.
The exact pathomechanism of how the 46/1 haplotype predisposes to the acquisition of acute myelomonocytic leukemia, and how it influences the outcome of NK-AML, is unknown. Two possible hypotheses have been proposed in the case of myeloproliferative neoplasms and both theories may be applicable to AML. 5, 29 The "hypermutability hypothesis", suggesting genomic instability at the JAK2 locus, is supported by the preferential acquisition of JAK2 V617F on the 46/1 allele in myeloproliferative neoplasms. On the other hand, the JAK2 gene was thoroughly resequenced in AML, and no acquired JAK2 mutations were observed in AML. 30 Enhanced susceptibility to DNA damage was estimated by comet assays in peripheral blood leukocytes of healthy 46/1 carriers indicating genomic instability affecting not exclusively the JAK2 locus. 31 The "fertile ground hypothesis" suggests that 46/1 haplotype carriers may have subtle differences in JAK2 function compared to 46/1 non-carriers, which increase the predisposition to clonal myeloproliferation. Indeed, healthy 46/1 haplotype carriers were reported to have reduced granulocytemacrophage colony formation. 5 The marked difference in death rate caused by infections (46.8% in carriers versus 23.5% in non-carriers, P=0.038) observed in our study may be explained by a functional alteration of the JAK2 associated with the 46/1 haplotype. Since JAK2 plays a central role in the signaling of diverse myeloid and lymphoid cytokine receptors (including granulocyte-macrophage colony-stimulating factor, GM-CSF), altered JAK2 function might delay bone marrow reconstruction and cause impaired immune defense after chemotherapy, resulting in more severe infectious complications.
Interestingly, genome-wide association studies found an association between JAK2 46/1 haplotype and inflammatory bowel disease. The impairment of JAK2 function was suggested to affect interleukin-23 signaling and the differentiation of pro-inflammatory T cells (Th17) in inflammatory bowel disease. [31] [32] [33] [34] On the other hand, several lines of evidence suggest that there is defective GM-CSF signaling in inflammatory bowel disease: decreased GM-CSF secretion, 35 neutralizing autoantibodies against GM-CSF, 36 and defective GM-CSF receptor expression and function 37 were described as characteristic features of inflammatory bowel disease. Compromised GM-CSF signaling resulting in functional abnormality of neutrophils and macrophages facilitates the invasion of the epithelial barrier by intestinal bacteria. The association of JAK2 46/1 haplotype with inflammatory bowel disease further supports the hypothesis that the 46/1 haplotype may be associated with a functional variant of JAK2.
In summary, the JAK2 46/1 haplotype influences morphological distribution increasing a predisposition to the acute myelomonocytoid form. Our data indicate that the JAK2 germline 46/1 haplotype may be an independent adverse prognostic factor affecting the severity of infections occurring during treatment in NK-AML. Prospective studies with larger numbers of AML patients are warranted to confirm our result. This finding may be useful in selecting riskadapted treatment strategies in intermediate-risk AML, or in identifying a possible treatment modifying factor in therapies targeting the JAK2 pathway in AML. 
Authorship and Disclosures
